PD-1 immunotherapy before mastectomy linked to higher opioid use

Immunotherapy has revolutionized the treatment of many cancers, and nowhere has its impact been more dramatic than in breast cancers that were once considered among the most difficult to treat. Drugs known as PD-1 inhibitors, including pembrolizumab and nivolumab, work by releasing the molecular brakes that tumors place on immune cells, allowing T cells to recognize and destroy malignant tissue. When combined with chemotherapy before surgery, a strategy known as neoadjuvant therapy, these agents have produced striking improvements in pathological complete response rates and long-term survival, particularly in triple-negative and high-risk hormone receptor-positive breast cancers. Yet a new study suggests that this therapeutic triumph may carry an unexpected and largely overlooked cost for patients undergoing breast surgery: significantly greater pain and a markedly higher need for opioids in the critical hours and weeks following mastectomy with reconstruction.

The research, led by Tyler P. Shern, Victoria Chamberlain, Logan R. Holt and colleagues in the Division of Breast Surgery at Mass General Brigham in Boston, and published in Breast Cancer Research and Treatment, offers some of the clearest clinical evidence to date that checkpoint blockade can alter how patients experience surgical pain. The investigators retrospectively reviewed 277 consecutive patients who underwent mastectomy with immediate reconstruction after neoadjuvant chemotherapy between 2020 and 2024. Of these, 54 had received a PD-1 inhibitor as part of their neoadjuvant regimen, while 223 received chemotherapy without immune checkpoint blockade. By comparing opioid consumption measured in oral morphine equivalents, pain scores recorded in the post-anesthesia care unit, and prescription refill patterns after discharge, the team was able to quantify, for the first time in this surgical population, what laboratory scientists had suspected for years: blocking PD-1 signaling appears to blunt the effectiveness of opioid analgesia.

The biology behind this finding is as intriguing as the clinical result. PD-1 and its ligand PD-L1 are best known as immune checkpoints, but research over the past decade has revealed that the PD-1/PD-L1 axis also operates within the nervous system. PD-L1 expressed on neurons suppresses nociceptive signaling, dampening both acute and chronic pain, and this natural analgesic system appears to work in concert with opioid receptors. Crucially, PD-1 signaling has been shown to modulate the activity of the µ-opioid receptor, the molecular target of morphine and most perioperative opioids. Animal studies have demonstrated that anti-PD-1 treatment can significantly impair opioid antinociception, and a 2020 study in Science Translational Medicine found that anti-PD-1 therapy reduced opioid effectiveness not only in rodents but also in nonhuman primates. The new clinical data suggest this phenomenon translates to human surgical patients as well.

The numbers from the Boston cohort are striking. Patients who had received neoadjuvant chemotherapy with a PD-1 inhibitor required an average of 3.5 oral morphine equivalents per hour in the post-anesthesia care unit, compared with 2.1 per hour in patients who received chemotherapy alone, a difference that was statistically significant. Their maximum pain scores in the immediate recovery period were also higher, averaging 6.3 on the standard numeric pain scale compared with 5.4 for the control group. The disparities did not end at discharge. Nearly 39 percent of patients in the PD-1 group required an opioid refill after leaving the hospital, versus only 17 percent of those who had not received the immunotherapy. In practical terms, more than one in three patients exposed to PD-1 blockade needed additional opioids to manage their pain, more than double the rate of their peers.

To ensure that these differences were not simply artifacts of patient selection, the researchers performed multivariable statistical analyses adjusting for a range of clinical and procedural variables. They found that PD-1-based neoadjuvant therapy independently predicted higher opioid use per hour in the recovery unit, alongside breast volume greater than 700 cubic centimeters and the use of preoperative analgesic medications. For post-discharge refills, PD-1 therapy was by far the strongest predictor, increasing the odds of needing a refill by roughly three and a half times, while axillary lymph node dissection also independently increased refill likelihood. Interestingly, the two groups were comparable in their preoperative analgesic use and intraoperative opioid administration, meaning that the divergence in pain and opioid consumption emerged precisely when patients awakened from surgery, the moment when the interplay between immune signaling and analgesic response would be expected to matter most.

The study population does introduce some complexity in interpretation. Patients in the PD-1 group were more likely to carry BRCA1 or BRCA2 mutations, with rates of nearly 39 percent compared with just over 7 percent in the control group, reflecting current trial designs that enroll germline mutation carriers into immunotherapy protocols. They were also more likely to undergo bilateral surgery, at 92.6 percent versus 67.7 percent, and sentinel lymph node biopsy, both of which are associated with greater surgical burden and pain. However, the statistical models accounted for these imbalances, and the independent association between PD-1 exposure and increased opioid requirement persisted. This careful adjustment strengthens the argument that the immunotherapy itself, rather than the biology of the tumors or the extent of surgery, drove the differences in analgesic consumption.

The findings arrive at a moment when immunotherapy is expanding rapidly across the breast cancer landscape. Landmark trials such as KEYNOTE-522 established pembrolizumab plus chemotherapy as standard care for high-risk early triple-negative breast cancer, and more recent phase 3 studies have extended the approach to estrogen receptor-positive disease, with nivolumab and pembrolizumab demonstrating event-free survival benefits in randomized trials. Additionally, novel combinations pairing PD-1 inhibitors with PARP inhibitors such as niraparib in BRCA-mutated breast cancer are advancing through clinical development. As the population of patients arriving in the operating room after PD-1 exposure grows, anesthesiologists and surgeons will increasingly encounter the analgesic challenge this study documents, often without realizing that their patient’s immunotherapy history may be reshaping their pain response.

The clinical implications extend beyond the recovery room. Enhanced recovery after surgery protocols and multimodal analgesia strategies emphasize minimizing opioid exposure, and prior work from the same surgical group has shown that mastectomy with reconstruction can be safely performed in ambulatory settings with low opioid requirements. If PD-1 inhibitors undermine the efficacy of opioid-based analgesia, perioperative teams may need to lean more heavily on non-opioid modalities, including regional nerve blocks, acetaminophen, nonsteroidal anti-inflammatory drugs, and agents such as gabapentinoids, to achieve adequate pain control without escalating opioid doses that may be pharmacologically less effective and carry their own risks. Conversely, the study also raises questions flowing in the other direction: opioids themselves have immunosuppressive properties, and preclinical research suggests morphine can blunt responses to immune checkpoint inhibitors, creating a potentially vicious cycle in which immunotherapy reduces opioid efficacy while opioids may undermine immunotherapy.

The researchers are careful to frame their results within the limitations of a retrospective, single-institution design. The PD-1 group was relatively small, at 54 patients, and the study relied on chart review rather than prospective pain assessments. Confounding by unmeasured variables, such as differences in tumor biology or reconstruction technique, cannot be entirely excluded. Nonetheless, the biological plausibility provided by the neuroimmunology literature, combined with concordant findings from other surgical populations, including increased perioperative opioid consumption reported in patients receiving neoadjuvant immunotherapy for esophageal and non-small-cell lung cancers, lends considerable weight to the conclusions. The consistency across tumor types suggests that impaired opioid analgesia may be a class effect of checkpoint blockade rather than a curiosity specific to breast surgery.

For now, the most important message is one of awareness. Patients who have received PD-1 inhibitors before breast surgery are not more fragile or less resilient, but their nervous systems may respond differently to standard analgesic protocols. Anesthesiologists planning perioperative care, surgeons counseling patients about recovery expectations, and oncologists sequencing systemic therapy all stand to benefit from knowing that checkpoint blockade can influence pain pathways in ways that extend far beyond the tumor microenvironment. As immunotherapy continues its march into earlier stages of cancer treatment, the medical community will need to integrate a more complete picture of these drugs’ physiological reach, one that encompasses not only tumor rejection and immune-related adverse events, but also the everyday, deeply human experience of postoperative pain.